Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy
Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board
Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses
Lund, Sweden, 3 June 2025 – Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces the appointments of Dr Cristina Csimma as an independent member of its Board of Directors, and Prof Ignacio Melero and Prof Brian Brown to its Clinical and Scientific Advisory Board. The appointments mark a significant step on Asgard’s transition to a drug development company, as it advances its lead asset AT-108 towards clinical trials.
